Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis…
Articles by Steve Bryson, PhD
Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching,…
A robotic-assisted Kasai surgical procedure results in less blood loss, faster bowel function recovery, and greater rates of clearing…
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim…
An international team of researchers using different experimental approaches identified two distinct types of metabolic dysfunction-associated steatotic liver disease (MASLD),…
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to…
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous…
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children…
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of…
Women who conceive with the help of in vitro fertilization (IVF) — a commonly used assisted reproductive technology — are…